1374744-69-0
Chemical Structure
Fedratinib hydrochloride hydrate
Synonym(s): TG-101348 hydrochloride hydrate; SAR 302503 hydrochloride hydrate
- CAS No.: 1374744-69-0
- Formula:C27H40Cl2N6O4S
- Molecular Weight:615.62
IUPAC Name: N-(tert-butyl)-3-((5-methyl-2-((4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)amino)pyrimidin-4-yl)amino)benzenesulfonamide dihydrochloride hydrate
InChIKey: QAFZLTVOFJHYDF-UHFFFAOYSA-N
SMILES: [H]Cl.[H]O[H].[H]Cl.O=S(C1=CC=CC(NC2=NC(NC3=CC=C(C=C3)OCCN4CCCC4)=NC=C2C)=C1)(NC(C)(C)C)=O
Biological Activity: Fedratinib hydrochloride hydrate (TG-101348 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC50s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib hydrochloride hydrate shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib hydrochloride hydrate induces cancer cell apoptosis and has the potential for myeloproliferative disorders research[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Fedratinib hydrochloride hydrate | 99.92% | Fedratinib hydrochloride hydrate (TG-101348 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC50s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib hydrochloride hydrate shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib hydrochloride hydrate induces cancer cell apoptosis and has the potential for myeloproliferative disorders research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Fedratinib hydrochloride hydrate (Standard) | ≥98% | Fedratinib (hydrochloride hydrate) (Standard) is the analytical standard of Fedratinib (hydrochloride hydrate). This product is intended for research and analytical applications. Fedratinib hydrochloride hydrate (TG-101348 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC50s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib hydrochloride hydrate shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib hydrochloride hydrate induces cancer cell apoptosis and has the potential for myeloproliferative disorders research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 0.97
HY-10409Fedratinib -
Similarity Score 0.83
HY-162031MMT3-72-M2 -
Similarity Score 0.77
HY-149283JAK/HDAC-IN-2 -
Similarity Score 0.76
HY-18301JAK-IN-35 -
Similarity Score 0.74
HY-10410RTG101209 (Standard) -
Similarity Score 0.72
HY-14986JAK-IN-32 -
Similarity Score 0.69
HY-156273HDAC/JAK/BRD4-IN-1 -
Similarity Score 0.68
HY-149284JAK/HDAC-IN-3 -
Similarity Score 0.67
HY-172089TG101209 analog 1 -
Explore the MedChemAI to find more analogs
References
- [1]. Wernig G, et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell. 2008 Apr;13(4):311-20. [Content Brief]
- [2]. Geron I, et al. Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors. Cancer Cell. 2008 Apr;13(4):321-30. [Content Brief]
